Ashish M. Kamat
University of Texas MD Anderson Cancer Center
CancerInternal medicineUrologySurgeryPathologyOncologyRetrospective cohort studyStage (cooking)CystectomyChemotherapyCarcinomaDiseaseBladder cancerIn patientNon muscle invasiveUrothelial carcinomaCancer researchClinical trialMedicineBiology
665Publications
76H-index
13.8kCitations
Publications 617
Newest
#1Patrick J. Hensley (University of Texas MD Anderson Cancer Center)H-Index: 5
#2Kelly K. Bree (University of Texas MD Anderson Cancer Center)H-Index: 4
Last. Charles C. Guo (University of Texas MD Anderson Cancer Center)H-Index: 36
view all 0 authors...
Purpose null Data from the pre-neoadjuvant chemotherapy (NAC) era suggests patients who progress on BCG to muscle-invasive bladder cancer (P-MIBC) exhibit worse outcomes compared to de novo MIBC (D-MIBC). Herein, we investigate whether P-MIBC is an independent poor risk factor in the setting of contemporary NAC use. null Materials and methods null A review of patients who underwent radical cystectomy (RC) for cT2-3 MIBC from 2005-2018 was performed. Patients were stratified into high-risk (lymph...
Source
#1Mary E. Westerman (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Kelly K. Bree (University of Texas MD Anderson Cancer Center)H-Index: 4
Last. Neema Navai (University of Texas MD Anderson Cancer Center)H-Index: 15
view all 0 authors...
Abstract null null Objective null To assess the extent and adequacy of pre-operative sexual function (SF) counseling in females undergoing radical cystectomy (RC) and develop educational material to improve identified deficits. null null null Methods null A 10-question survey was electronically delivered to all females who underwent RC at a single institution between 2015 and 2020. 23 of 145 patients responded (15.9%). In addition, women on the Bladder Cancer Advocacy Network (BCAN) patient disc...
Source
#1Stephen B. Williams (UTMB: University of Texas Medical Branch)H-Index: 29
Last. Ashish M. Kamat (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 0 authors...
Abstract null null Objective null To determine the estimated budget impact to practices that incorporate blue light cystoscopy (BLC) with hexaminolevulinate HCl (HAL) for the surveillance of non-muscle-invasive bladder cancer (NMIBC) in the clinic setting. With the introduction of advanced technologies in the clinic setting such as HAL, further cost comparative research is needed to justify HAL as a high value option. null null null Material and methods null A budget impact model was developed f...
Source
#1Gianluca Giannarini (Misericordia University)H-Index: 33
#2Neeraj Agarwal (HCI: Huntsman Cancer Institute)H-Index: 61
Last. Andrea NecchiH-Index: 35
view all 0 authors...
Novel immune checkpoint inhibitors hold promise for non-muscle-invasive bladder cancer. Cooperation between urologists and other multidisciplinary bladder cancer specialists can surmount the challenges involved in using these agents in bladder-sparing approaches. This strategy could deliver a new era of comprehensive evaluation and multimodal treatment for this patient population.
Source
#1Niyati Lobo (University of Texas MD Anderson Cancer Center)H-Index: 2
#2Nathan A. Brooks (University of Texas MD Anderson Cancer Center)H-Index: 8
Last. Gary D. SteinbergH-Index: 51
view all 0 authors...
Bacillus Calmette-Guerin (BCG) is the most widely used vaccine worldwide and has been used to prevent tuberculosis for a century. BCG also stimulates an anti-tumour immune response, which urologists have harnessed for the treatment of non-muscle-invasive bladder cancer. A growing body of evidence indicates that BCG offers protection against various non-mycobacterial and viral infections. The non-specific effects of BCG occur via the induction of trained immunity and form the basis for the hypoth...
Source
#1Kelly K. Bree (University of Texas MD Anderson Cancer Center)H-Index: 4
#2Patrick J. Hensley (University of Texas MD Anderson Cancer Center)H-Index: 5
Last. Ashish M. Kamat (University of Texas MD Anderson Cancer Center)H-Index: 76
view all 0 authors...
PURPOSE Female sex has been implicated with higher stage at diagnosis and as a negative prognostic factor amongst patients with non-muscle invasive bladder cancer (NMIBC). Whether this holds true with contemporary management paradigms is unknown. We analyzed a cohort of patients treated with adequate bacillus Calmette-Guerin (BCG) for NMIBC in an effort to identify sex-specific influence on BCG response. METHODS An IRB-approved review of patients with NMIBC treated at our institution with at lea...
Source
#1Ryan L. Steinberg (UI: University of Iowa)H-Index: 12
#2Vignesh T. Packiam (UI: University of Iowa)H-Index: 14
Last. Donald L. Lamm (UA: University of Arizona)H-Index: 62
view all 0 authors...
Abstract null null Introduction null Repeat BCG induction remains an option for select non-muscle invasive bladder cancer (NMIBC) patients who fail initial therapy. Alternative salvage intravesical regimens such as Gemcitabine and Docetaxel (Gem/Doce) have been investigated. We aimed to compare the efficacy BCG plus interferon a-2b (BCG/IFN) and Gem/Doce in patients with recurrent NMIBC after a single prior BCG course. null null null Methods null The National Phase II BCG/IFN trial database and ...
Source
#1Arjun Vasant BalarH-Index: 20
#2Ashish M. Kamat (University of Texas MD Anderson Cancer Center)H-Index: 76
Last. Ronald de Wit (Erasmus University Medical Center)H-Index: 21
view all 18 authors...
Summary Background Standard treatment for high-risk non-muscle-invasive bladder cancer is transurethral resection of bladder tumour followed by intravesical BCG immunotherapy. However, despite high initial responses rates, up to 50% of patients have recurrence or become BCG-unresponsive. PD-1 pathway activation is implicated in BCG resistance. In the KEYNOTE-057 study, we evaluated pembrolizumab, a PD-1 inhibitor, in BCG-unresponsive non-muscle-invasive bladder cancer. Methods We did this open-l...
2 CitationsSource
#1Vinson Wai-Shun Chan (University of Leeds)H-Index: 3
#2Wei Shen Tan (UCL: University College London)H-Index: 18
Last. Jeremy Yuen-Chun Teoh (CUHK: The Chinese University of Hong Kong)H-Index: 16
view all 26 authors...
PURPOSE: The COVID-19 pandemic has led to the cancellation or deferment of many elective cancer surgeries. We performed a systematic review on the oncological effects of delayed surgery for patients with localised or metastatic renal cell carcinoma (RCC) in the targeted therapy (TT) era. METHOD: The protocol of this review is registered on PROSPERO(CRD42020190882). A comprehensive literature search was performed on Medline, Embase and Cochrane CENTRAL using MeSH terms and keywords for randomised...
Source
Source